To evaluate aripiprazole in the treatment of schizophrenia, including a comparison of available agents, pharmacology, pharmacokinetics, assessment of clinical trials, and adverse effects.
Data Sources:
A MEDLINE search (1962–March 2003) was conducted for primary and secondary sources. Search terms included OPC-14597, aripiprazole, typical antipsychotics, atypical antipsychotics, and schizophrenia. The Review and Evaluation of Clinical Data from NDA 21-436 was accessed from the FDA Web site.
Study Selection:
All articles retrieved were evaluated, and the most appropriate studies were selected. Relevant poster presentations were included.
Data Synthesis:
Aripiprazole is a potent partial agonist/antagonist at the dopamine D2 receptor, as well as a partial agonist at the serotonin 5-HT1A receptor and an antagonist at the 5-HT2A receptor. Clinical trials were assessed for information on dosing, side effects, and adverse drug reactions.
Conclusions:
Aripiprazole appears to be superior to placebo for the treatment of schizophrenia, with a favorable adverse effect profile.
Get full access to this article
View all access options for this article.
References
1.
RobinsLNLockeBZReigierDA, eds. An overview of psychiatric disorders in America. In: Psychiatric disorders in America: the epidemiological catchment area study. New York: Free Press, 1991: 328–66.
2.
LopezA.The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Published by the Harvard School of Public Health on behalf of the World Health Organization. Boston: Harvard University Press, 1996.
3.
CarlssonA.The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology1988; 1: 179–86.
4.
Diagnostic and statistical manual of mental disorders. 4th ed.Washington, DC: American Psychiatric Association, 1994.
5.
MansourAMeador-WoodruffJLopezJWatsonSSchatzbergANemeroffC, eds. Biochemical anatomy: Insights into the cell biology and pharmacology of the dopamine and serotonin systems in the brain. In: SchatzbergANemeroffC, eds. Textbook of psychopharmacology. 2nd ed.Washington, DC: American Psychiatric Association Press, 1998: 45–59.
6.
StahlS.Psychosis and schizophrenia. In: Essential psychopharmacology: neuroscientific basis of practical applications. 2nd ed.Cambridge University Press2000: 365–458.
7.
BaldessariniRTaraziF.Drugs and the treatment of psychiatric disorders. In: GilmanAGRallTTaylorP, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed.New York: McGraw-Hill, 2001: 485–520.
8.
WorrelJMarkenPBeckmanSRuehterV.Atypical antipsychotic agents: A critical review. Am J Health Syst Pharm2000; 57: 23–5.
9.
SharmaTMocklerD.The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol1998; 18 (suppl 1): 12S–9S.
10.
MillanM.Improving the treatment of schizophrenia: Focus on serotonin (5HT1A) receptors. Pharmacol Exper Ther2000; 295: 853–61.
11.
EreshefskyLTran-JohnsonTKWantanabeMD. Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics. Clin Pharm1990; 9: 682–707.
12.
StahlSM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics. Part 1: “Goldilocks” actions at dopamine receptors. J Clin Psychiatry2001; 62: 841–2.
13.
StahlSM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics. Part 2: Illustrating their mechanism of action. J Clin Psychiatry2001; 62: 923–4.
14.
BurrisKDMolskiTFXuCRyanETottoriKKikuchiT, Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exper Ther2002; 302: 381–9.
15.
InoueTDomaeMYamadaKFurukawaT.Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exper Ther1996; 277: 137–43.
16.
KikuchiTTottoriKUwahodoYHiroseTMiwaTOshiroY, 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exper Ther1995; 274: 329–36.
17.
SembaJWatanabeAKitoSToruM.Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropsychopharmacology1995; 34: 785–91.
18.
KikuchiTTottoriKUwahodoYMiwaTHiroseTFujiwaraK, 7-{4-[4-(2.3-dichlorophenyl)-1-piperazinyl] butyloxy}-3-4dihydro-2(1H)-quinolinone (OPC-14597), a unique antipsychotic drug candidate with both presynaptic dopamine autoreceptor agonist activity and postsynaptic D2 receptor antagonistic activity. Neuropsychopharmacology1994; 10 (suppl): 194S.
19.
SibleyDGonzalezABurgessLMaxSAtkinsonBZhangL.Pharmacological characterization of OPC-14597, a novel antipsychotic agent, using cloned dopamine and serotonin receptors. Neuropsychopharmacology1994; 10 (suppl): 252S.
20.
YokoiFGrunderGBiziereKStephaneMDoganASDannalsRF, Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology2002; 27: 248–59.
21.
InoueAMikiSSetoMKikuchiTMoritaSUedaH, Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol1997; 321: 105–11.
22.
LawlerCPPrioleauCLewisMMMakCJiangDSchetzJA, Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology1999; 20: 612–27.
23.
JordanSKoprivicaVChenRTottoriKKikuchiTAltarCA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol2002; 441: 137–40.
24.
Newman-TancrediAGavaudanSConteCChaputCTouzardMVerrieleL, Agonist and antagonist actions of antipsychotic agents at 5-HT1a receptors: a [35S] GTP yS binding study. Eur J Pharmacol1998; 355: 245–56.
25.
NashJFMeltzerHY. Effects of gepirone and ipsapirone on the stimulated and unstimulated secretion of prolactin in the rat. J Pharmacol Exp Ther1989; 249: 236–41.
MallikaarjunSSalazarDEBramerSL. The pharmacokinetics and tolerability of aripiprazole following single and multiple oral dose administration in normal volunteers (poster). Presented at: 22nd Congress of the Collegium Internationale Neuropsychopharmacologicum, Brussels, Belgium, July 9–13, 2000.
28.
Prescribing information. Abilify (aripiprazole). Bristol-Meyers Squibb. November 2002.
29.
BlumerJFindlingRKauffmanRBattersonRGilbertDBramerS, Pharmacokinetics, tolerability, and safety of aripiprazole in adolescents and children with conduct disorder (poster). Presented at: American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, March 24–27, 2002.
30.
MallikaarjunSSalazarDEBramerSL. The effects of age and gender on the pharmacokinetics of aripiprazole (poster). Presented at: American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, March 24–27, 2002.
31.
KaneJMCarsonWHSahaARMcQuadeRDIngenitoGGZimbroffDL, Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry2002; 63: 763–71.
32.
PotkinSSahaAKujawaMCarsonWHAliMStockE, Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry2003; 60: 681–90.
33.
KaySRFiszbeinAOplerLA. The Positive and Negative Syndrome Scale for schizophrenia. Schizophren Bull1987; 13: 261–76.
34.
OverallJEGorhamDR. The Brief Psychiatric Rating Scale. Psychol Rep1962; 10: 799–812.
35.
Clinical Global Impressions (CGI). National Institute of Mental Health. In: GuyW.ECDEU assessment manual for psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976: 218–22.
36.
BarnesTRE. A rating scale for drug induced akathisia. Br J Psychiatry1989; 154: 672–6.
37.
SimpsonGMAngusJWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl1970; 45 (suppl 212): 11–9.
38.
Abnormal Involuntary Movement Scale (AIMS). In: GuyW.ECDEU assessment manual for psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976: 534–7.
39.
CarsonWCarsonWHPigottTAliMWMcQuadeRDTorbeynsAF, Aripiprazole vs. placebo in the treatment of chronic schizophrenia (poster). Presented at: Collegium Internationale Neuro-Psychopharmacologium Meeting. Montréal, June 23–27, 2002.
40.
KujawaMSahaARIngenitoGGAliMWLouXArchibaldDG, Aripiprazole for long-term maintenance of schizophrenia (poster). Presented at: Collegium Internationale Neuro-Psychopharmacologium Meeting. Montréal, June 23–27, 2002.
41.
CornblattBKernRSCarsonWHAliMWLouXGreenM.Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis (poster). Presented at: Collegium Internationale Neuro-Psychopharmacologium Meeting. Montréal, June 23–27, 2002.
42.
CaniveJThomaREdgarCHanlonFMosesSWeisendM, P50 Sensory gating in schizophrenia: treatment with conventional antipsychotics (poster). Presented at: Collegium Internationale Neuro-Psychopharmacologium Meeting. Montréal, June 23–27, 2002.
43.
JodyDMarcusRKeckPSahaARIwamotoTTourkodimitrisS, Aripiprazole versus placebo in acute mania (poster). Presented at: Collegium Internationale Neuro-Psychopharmacologium Meeting. Montréal, June 23–27, 2002.
44.
MarderSMcQuadeRStockEKaplitaSMarcusRSaffermanA, Aripiprazole in the treatement of schizophrenia: Safety and tolerability in short-term placebo controlled trials. Schizophr Res2003; 61: 123–36.
45.
SahaAAliMWIngenitoGGWilberRLouXBramerS.Safety and tolerability of aripiprazole at doses higher than 30 mg (poster). Presented at: Collegium Internationale Neuro-Psychopharmacologium Meeting. Montréal, June 23–27, 2002.
46.
CaseyDSahaARAliMWJodyDNKujawaMJStockEG, Switching to aripiprazole monotherapy (poster). Presented at: Collegium Internationale Neuro-Psychopharmacologium Meeting. Montréal, June 23–27, 2002.
